Literature DB >> 17988217

Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria.

Patrizia Ferroni1, Maria Teresa Guagnano, Angela Falco, Vincenzo Paoletti, Maria Rosaria Manigrasso, Noemi Michetti, Francesca Santilli, Fiorella Guadagni, Stefania Basili, Giovanni Davì.   

Abstract

Increased levels of sCD40L (soluble CD40 ligand) have been associated with enhanced in vivo platelet activation, and may represent a molecular link between inflammation and a prothrombotic state. The aim of the present study was to analyse the relationship between platelet activation, endothelial dysfunction, low-grade inflammation and sCD40L in patients with hypertension with or without MA (microalbuminuria). A cross-sectional comparison of sCD40L levels was performed in 25 patients with MH (essential hypertension with MA) pair-matched for gender and age with 25 patients with EH (essential hypertension) and 25 HS (healthy subjects with normotension). Circulating levels of CRP (C-reactive protein), a marker of inflammation, sP-selectin (soluble P-selectin), a marker of in vivo platelet activation, and ADMA (asymmetric dimethylarginine) and vWF (von Willebrand factor), markers of endothelial dysfunction, were analysed in each subject. sCD40L levels were increased in patients with MH compared with either patients with EH (P<0.001) or HS (P<0.0001). A highly significant correlation between plasma sCD40L and sP-selectin (P<0.0001), vWF (P<0.001) or CRP levels (P<0.05) was observed in patients with MH. Multivariate regression analysis showed that sP-selectin was the strongest independent predictor of sCD40L levels (P<0.0001) in patients with MH. Patients with hypertension with both vWF and CRP levels above the median had the highest sCD40L levels (P<0.0001). Factorial ANOVA of all of the patients with hypertension confirmed that only patients with MH with low-grade inflammation had elevated levels of sCD40L. In conclusion, sCD40L levels appear to discriminate a subset of patients characterized by MA and low-grade inflammation, suggesting that inhibition of the CD40/CD40L system may represent a potential therapeutic target in subjects with hypertension at a high risk of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17988217     DOI: 10.1042/CS20070307

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead.

Authors:  Rigas Kalaitzidis; George Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738

2.  Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.

Authors:  Li-Xin Jia; Guan-Ming Qi; Ou Liu; Tao-Tao Li; Min Yang; Wei Cui; Wen-Mei Zhang; Yong-Fen Qi; Jie Du
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

Review 3.  Effects of Nutrients on Platelet Function: A Modifiable Link between Metabolic Syndrome and Neurodegeneration?

Authors:  Ilse A C Arnoldussen; Renger F Witkamp
Journal:  Biomolecules       Date:  2021-10-04

4.  Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability.

Authors:  Yen Chin Koay; Yung-Chih Chen; Jibran A Wali; Alison W S Luk; Mengbo Li; Hemavarni Doma; Rosa Reimark; Maria T K Zaldivia; Habteab T Habtom; Ashley E Franks; Gabrielle Fusco-Allison; Jean Yang; Andrew Holmes; Stephen J Simpson; Karlheinz Peter; John F O'Sullivan
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

5.  P‑selectin increases angiotensin II‑induced cardiac inflammation and fibrosis via platelet activation.

Authors:  Gaizhen Liu; Bin Liang; Xiaosu Song; Rui Bai; Weiwei Qin; Xu Sun; Yan Lu; Yunfei Bian; Chuanshi Xiao
Journal:  Mol Med Rep       Date:  2016-04-25       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.